Larotrectinib is highly active in patients with advanced recurrent TRK fusion thyroid (TC) and salivary gland cancers (SGC) Meeting Abstract
| Authors: | Wirth, L.; Drilon, A.; Albert, C.; Farago, A.; El-Diery, W.; Ma, P.; Sohal, D.; Raez, L.; Baik, C.; Brose, M. S.; Doebele, R.; Cox, M.; Ku, N.; Hong, D. |
| Abstract Title: | Larotrectinib is highly active in patients with advanced recurrent TRK fusion thyroid (TC) and salivary gland cancers (SGC) |
| Meeting Title: | 2018 Multidisciplinary Head and Neck Cancers Symposium |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 100 |
| Issue: | 5 |
| Meeting Dates: | 2018 Feb 15-17 |
| Meeting Location: | Scottsdale, AZ |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-04-01 |
| Start Page: | 1318 |
| Language: | English |
| ACCESSION: | WOS:000428145600065 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ijrobp.2017.12.303 |
| Notes: | Meeting Abstract: LBA13 -- Source: Wos |
